Study guide

2.3 Pharmacological Effects on Sleep Architecture & Waveforms

BRPT Certified Polysomnographic Technician CPSGT

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: CPSGT Overview, Eligibility & Credentialing

1.1 CPSGT Exam Structure, Scoring & Test Logistics 1.2 Eligibility Pathways, STAR Programs & Application Requirements 1.3 Scope of Practice, Credential Progression & Ethics

2 Chapter 2: Patient Assessment, Clinical Intake & Medication Effects

2.1 Clinical Indications & Physician Order Verification 2.2 Clinical History, Screening Tools & Physical Assessment 2.3 Pharmacological Effects on Sleep Architecture & Waveforms

3 Chapter 3: International 10-20 System, Montage Setup & Bio-Calibrations

3.1 International 10-20 System Cranial Landmarks & Measurements 3.2 Recommended EEG Derivations & EOG Placements 3.3 Chin EMG, Leg EMG, ECG & Respiratory Sensor Montages 3.4 Skin Preparation, Impedance Optimization & Bio-Calibrations

4 Chapter 4: Testing Protocols, Signal Processing & Artifact Management

4.1 Diagnostic Protocols: Adult PSG, Pediatric Testing & HSAT 4.2 Daytime Sleep Testing Protocols: MSLT & MWT 4.3 Signal Processing: Filters, Sampling Rates & Display Parameters 4.4 Artifact Recognition, Troubleshooting & ECG Dysrhythmias

5 Chapter 5: Sleep Staging, Arousal Rules & Physiologic Event Scoring

5.1 AASM Adult Sleep Stage Scoring Rules 5.2 Pediatric Sleep Staging & AASM EEG Arousal Rules 5.3 AASM Respiratory Event Scoring Rules 5.4 Movement Disorders, Parasomnias & Neurological Events

6 Chapter 6: Polysomnographic Calculations, Indices & Data Reporting

6.1 Sleep Architecture, Latency & Efficiency Calculations 6.2 Respiratory Indices & OSA Severity Grading 6.3 Oxygenation, Arousal & Periodic Limb Movement Indices 6.4 Comprehensive Technologist Morning Reporting & Quality Assurance

7 Chapter 7: PAP Modalities, Titration Protocols & Troubleshooting

7.1 PAP Therapy Modalities, Mechanics & Interface Selection 7.2 AASM CPAP & BiPAP Titration Protocols and Algorithms 7.3 Split-Night Protocols & AASM Titration Quality Grading 7.4 PAP Troubleshooting, Leaks & Side Effect Management

8 Chapter 8: Supplemental Oxygen, Patient Safety & Professional Practice

8.1 Supplemental Oxygen Titration & Delivery Protocols 8.2 In-Lab Medical Emergencies & Clinical Response Protocols 8.3 Electrical Safety, Environmental Protocols & Infection Control 8.4 Patient Communication, HIPAA & Professional Ethics

2.3 Pharmacological Effects on Sleep Architecture & Waveforms

Key Takeaways Explain This Topic AI

Central nervous system medications exert profound effects on sleep architecture, stage distribution, neurophysiologic waveforms, and central respiratory drive.

Benzodiazepines and classical sedative-hypnotics increase Stage N2 sleep and sleep spindle density while significantly suppressing Stage N3 slow-wave sleep and Stage REM sleep.

Antidepressants (SSRIs, SNRIs, TCAs, MAOIs) are potent REM suppressants that prolong REM latency, reduce total REM percentage, and frequently induce REM Sleep Without Atonia (RSWA).

Chronic opioids depress central respiratory pacemakers, causing central sleep apneas and ataxic breathing, while acute alcohol ingestion induces early slow-wave sleep followed by second-half REM rebound and severe upper airway collapse.

Last updated: August 2026

2.3 Pharmacological Effects on Sleep Architecture & Waveforms

In clinical polysomnography, interpreting sleep architecture, identifying EEG patterns, and scoring respiratory events requires a comprehensive understanding of pharmacology. Medications acting on the central nervous system (CNS) alter the balance of key neurotransmitters—including GABA, serotonin ( 5 -HT 5\text{-HT} 5 -HT ), norepinephrine (NE), dopamine (DA), acetylcholine (ACh), histamine, and orexin/hypocretin .

On the CPSGT examination , technicians are expected to identify the characteristic changes in sleep stage percentages, electroencephalographic waveforms (such as beta activity and sleep spindle density), muscle tone, and respiratory drive produced by prescribed drugs, over-the-counter supplements, and substance use.

1. Sedative-Hypnotics & GABA-A Receptor Modulators

Gamma-aminobutyric acid (GABA) is the primary inhibitory neurotransmitter in the mammalian brain. Pharmacological agents that enhance GABAergic transmission at the G A B A A GABA_A G A B A A ​ receptor complex exert prominent sedative, anxiolytic, and hypnotic effects. +-----------------------------------------------------------------------------+

  • | GABA-A AGONIST SLEEP ARCHITECTURE PROFILE |
  • | |
  • | PARAMETER BENZODIAZEPINES NON-BZDs (Z-DRUGS) |
  • | ------------------------- --------------------- -------------------- |
  • | Sleep Onset Latency (SOL) Decreased (Faster) Decreased (Faster) |
  • | Wake After Sleep Onset Decreased (Less wake) Decreased |
  • | Total Sleep Time (TST) Increased Increased |
  • | Stage N1 Sleep Decreased Decreased / Unchanged |
  • | Stage N2 Sleep Markedly INCREASED Mildly Increased |
  • | Stage N3 (Slow Wave Sleep) Markedly DECREASED Preserved / Unchanged |
  • | Stage REM Sleep Decreased Preserved / Unchanged |
  • | Characteristic Waveform High Beta / Spindles Minimal Beta |
  • +-----------------------------------------------------------------------------+
  • A. Benzodiazepines (e.g., Clonazepam, Lorazepam, Diazepam, Temazepam, Alprazolam)

Mechanism: Positive allosteric modulators of the G A B A A GABA_A G A B A A ​ receptor, increasing chloride channel opening frequency.

Polysomnographic Effects:

Shorten sleep onset latency and reduce Wake After Sleep Onset (WASO), increasing Total Sleep Time (TST).

Marked Increase in Stage N2 Sleep: Stage N2 percentage increases significantly.

EEG Signature: Induce prominent fast beta activity (13–30 Hz) , often referred to as "benzodiazepine fast activity," and significantly increase sleep spindle density (11–16 Hz) .

Suppression of N3 and REM: Cause marked reduction in Stage N3 slow-wave sleep (delta power) and moderate suppression of Stage REM.

Withdrawal Effects: Abrupt cessation precipitates severe rebound insomnia , increased WASO, and REM rebound with intense nightmares.

B. Non-Benzodiazepine Receptor Agonists / "Z-Drugs" (Zolpidem, Eszopiclone, Zaleplon)

Mechanism: Selectively bind to the α 1 \alpha_1 α 1 ​ subunit of the G A B A A GABA_A G A B A A ​ receptor, conferring hypnotic efficacy with less muscle relaxant or anxiolytic activity.

Polysomnographic Effects:

Shorten sleep latency and improve sleep maintenance with minimal disruption to baseline sleep architecture .

Unlike traditional benzodiazepines, Z-drugs largely preserve Stage N3 slow-wave sleep and Stage REM sleep .

Induce less fast beta activity than classical benzodiazepines.

C. Barbiturates (e.g., Phenobarbital, Secobarbital)

Mechanism: Increase the duration of G A B A A GABA_A G A B A A ​ chloride channel opening.

Polysomnographic Effects: Profound suppression of both Stage REM and Stage N3 sleep, with prominent widespread high-voltage beta activity. Rarely used today due to high toxicity and dependence liability.

2. Antidepressants & Monoaminergic Agents

Most antidepressants augment monoaminergic signaling (serotonin, norepinephrine, dopamine) in the brainstem and forebrain. Because monoamines are the primary "REM-off" neurotransmitters that suppress the cholinergic "REM-on" neurons of the pedunculopontine tegmental (PPT) and laterodorsal tegmental (LDT) nuclei, antidepressants exert dramatic effects on REM sleep. +-----------------------------------------------------------------------------+

  • | ANTIDEPRESSANT IMPACT ON SLEEP ARCHITECTURE |
  • | |
  • | [SSRIs / SNRIs / TCAs / MAOIs] |
  • | - Profound REM Suppression ---> Marked Decrease in % REM (can drop to 0%) |
  • | - Prolonged REM Latency ---> REM onset delayed >120-200+ minutes |
  • | - REM Sleep Without Atonia---> Phasic / tonic muscle activity in REM |
  • | - Motor Activation ---> Exacerbation of RLS and PLMS |
  • | |
  • | [WITHDRAWAL REBOUND] |
  • | - Abrupt cessation causes massive REM REBOUND, nightmares, and sleep |
  • | fragmentation. |
  • +-----------------------------------------------------------------------------+
  • A. Selective Serotonin Reuptake Inhibitors (SSRIs) & SNRIs

Agents: Fluoxetine, Sertraline, Paroxetine, Citalopram, Escitalopram, Venlafaxine, Duloxetine.

Polysomnographic Effects:

Potent REM Suppression: Significant decrease in total Stage REM percentage.

Marked Prolongation of REM Latency: The interval from sleep onset to the first epoch of REM is drastically increased (often > 150 – 200 minutes >150\text{--}200\text{ minutes} > 150 – 200 minutes ).

REM Sleep Without Atonia (RSWA): Induce persistent tonic or phasic submental and tibial electromyographic (EMG) elevation during REM sleep, mimicking or unmasking REM Sleep Behavior Disorder (RBD) .

Exacerbation of Limb Movements: Frequently induce or worsen Periodic Limb Movements in Sleep (PLMS) and Restless Legs Syndrome (RLS).

Increase Stage N1 sleep and nocturnal microarousals.

B. Tricyclic Antidepressants (TCAs) & MAO Inhibitors (MAOIs)

TCAs (Amitriptyline, Nortriptyline, Clomipramine): Potent REM suppressors and REM latency prolongers. Secondary to anticholinergic and antihistaminergic ( H 1 H_1 H 1 ​ ) actions, they cause daytime sedation and dry mouth.

Low-Dose Doxepin (3–6 mg): Highly selective H 1 H_1 H 1 ​ receptor antagonist used for sleep maintenance insomnia; improves WASO and sleep efficiency without suppressing REM or N3 sleep.

MAOIs (Phenelzine, Tranylcypromine): The most extreme REM suppressors known; can completely eliminate Stage REM ( 0 % REM 0\%\text{ REM} 0% REM ) for months during chronic therapy.

C. Atypical Antidepressants (Trazodone, Mirtazapine, Bupropion)

Trazodone & Mirtazapine: Potent antagonists of 5 -HT 2 A 5\text{-HT}_{2A} 5 -HT 2 A ​ and H 1 H_1 H 1 ​ receptors. They promote sleep maintenance, increase Total Sleep Time, and increase or preserve Stage N3 slow-wave sleep without the severe REM suppression seen with SSRIs.

Bupropion (Wellbutrin): A norepinephrine-dopamine reuptake inhibitor (NDRI). Has minimal effect on REM sleep and does not suppress REM; in some patients, it may mildly increase REM percentage and shorten REM latency.

3. Central Nervous System Stimulants

Psychostimulants are prescribed for Attention-Deficit/Hyperactivity Disorder (ADHD), narcolepsy, and shift work sleep disorder.

Classical Stimulants (Methylphenidate, Dextroamphetamine, Mixed Amphetamine Salts):

Mechanism: Increase synaptic dopamine and norepinephrine concentrations.

Polysomnographic Effects: Significantly increase Sleep Onset Latency (SOL) , increase wakefulness (WASO), decrease Total Sleep Time (TST), reduce sleep efficiency, and suppress Stage REM sleep.

Clinical Testing Note: Must be discontinued/washed out (typically for 14 days under physician supervision) prior to diagnostic MSLT to avoid false-negative daytime sleep latencies.

Wakefulness-Promoting Agents (Modafinil, Armodafinil):

Selectively enhance dopamine signaling and hypothalamic histamine/orexin release.

Promote wakefulness and alertness without drastically disrupting nocturnal sleep architecture if taken early in the morning.

4. Opioids & Central Respiratory Depressants

Opioid medications (e.g., Morphine, Oxycodone, Methadone, Fentanyl, Buprenorphine) exert profound inhibitory actions on respiratory control centers in the brainstem. +-----------------------------------------------------------------------------+

  • | OPIOID RESPIRATORY & SLEEP PROFILE |
  • | |
  • | RESPIRATORY IMPACT: |
  • | - Depression of Pre-Bötzinger Complex (Medullary Respiratory Pacemaker) |
  • | - Induction of Central Sleep Apneas (CSA) |
  • | - Induction of Ataxic Breathing / Biot's Respiration (irregular rhythm) |
  • | - Variable Hypoxemia and Sleep-Related Hypoventilation |
  • | |
  • | SLEEP ARCHITECTURE IMPACT: |
  • | - Profound Reduction / Elimination of Stage N3 (Slow Wave Sleep) |
  • | - Reduction of Stage REM Sleep |
  • | - Marked Sleep Fragmentation & Frequent Microarousals |
  • | - Increase in Stage N1 (Light Sleep) |
  • +-----------------------------------------------------------------------------+

Ataxic Breathing (Biot's Respiration): An irregular, chaotic respiratory pattern with variable tidal volumes and irregular periods of apnea, characteristic of chronic opioid therapy.

Treatment-Emergent Challenges: Standard CPAP often fails to resolve opioid-induced central apneas and may exacerbate central events. Patients frequently require Adaptive Servo-Ventilation (ASV) or Bilevel PAP with a timed backup rate.

5. Cardiovascular Medications & Beta-Blockers

Lipophilic Beta-Blockers (Propranolol, Metoprolol): Cross the blood-brain barrier readily and inhibit nocturnal melatonin synthesis in the pineal gland. They cause sleep onset and maintenance insomnia, frequent nocturnal awakenings, nightmares, and modest REM suppression .

Hydrophilic Beta-Blockers (Atenolol, Nadolol): Do not easily cross the blood-brain barrier and cause significantly fewer central sleep disturbances.

6. Alcohol (Ethanol)

Alcohol is the most common self-administered hypnotic, but its pharmacokinetics produce a distinct biphasic effect across the sleep period. +-----------------------------------------------------------------------------+

  • | ALCOHOL'S BIPHASIC OVERNIGHT EFFECT |
  • | |
  • | FIRST HALF OF NIGHT (Rising/Elevated BAC) |
  • | [+] GABAergic stimulation accelerates sleep onset (Shortened Sleep Latency)|
  • | [+] Increase in Stage N3 Slow Wave Sleep |
  • | [-] Suppression of Stage REM Sleep |
  • | [-] Upper airway hypotonia: Genioglossus muscle relaxation worsens OSA |
  • | |
  • | SECOND HALF OF NIGHT (Metabolized to Acetaldehyde / BAC = 0) |
  • | [!] Acute Withdrawal & Sympathetic Autonomic Activation |
  • | [!] Severe Sleep Fragmentation & Frequent Arousals |
  • | [!] Intense REM REBOUND (Vivid nightmares, nocturnal sweating) |
  • | [!] Early morning awakening & insomnia |
  • +-----------------------------------------------------------------------------+

Upper Airway Collapsibility: Alcohol selectively relaxes the genioglossus and upper airway dilator muscles while simultaneously blunting the brainstem arousal response to hypoxia and hypercapnia. This causes longer apneas, deeper oxygen desaturations, and converts mild snoring into severe obstructive sleep apnea.

7. Master Pharmacology Reference Matrix

The following reference matrix consolidates the high-yield pharmacological effects tested on the CPSGT examination:

Drug Class / Agent Primary Sleep Architecture Impact Waveform / Neurological Effects Respiratory & Motor Effects

Benzodiazepines ; (Clonazepam, Lorazepam) ↑ \uparrow ↑ TST, ↑ ↑ \uparrow\uparrow ↑↑ N2, ↓ ↓ \downarrow\downarrow ↓↓ N3, ↓ \downarrow ↓ REM ↑ ↑ \uparrow\uparrow ↑↑ Fast Beta Activity (13–30 Hz), ↑ \uparrow ↑ Sleep Spindles Decreased upper airway muscle tone; mild respiratory depression.

Z-Drugs ; (Zolpidem, Eszopiclone) ↑ \uparrow ↑ TST, ↓ \downarrow ↓ SOL, Preserves N3 & REM Minimal beta activity; physiological waveforms preserved Minimal respiratory suppression at therapeutic doses.

SSRIs / SNRIs ; (Fluoxetine, Venlafaxine) ↓ ↓ \downarrow\downarrow ↓↓ % REM, ↑ ↑ \uparrow\uparrow ↑↑ REM Latency, ↑ \uparrow ↑ N1, ↑ \uparrow ↑ WASO REM Sleep Without Atonia (RSWA) with elevated muscle tone Exacerbates RLS and increases Periodic Limb Movements (PLMS).

Tricyclic Antidepressants ; (Amitriptyline) ↓ ↓ \downarrow\downarrow ↓↓ REM, ↑ \uparrow ↑ REM Latency, ↑ \uparrow ↑ TST Anticholinergic slowing; daytime somnolence May exacerbate RLS/PLMS; dry mouth.

MAO Inhibitors ; (Phenelzine) Complete suppression of REM ( 0 % REM 0\%\text{ REM} 0% REM ) Abolishes REM-on neuronal firing Profound REM rebound upon withdrawal.

Trazodone / Mirtazapine ↑ \uparrow ↑ TST, ↑ \uparrow ↑ N3 (Slow Wave Sleep), Preserves REM Enhances delta power; minimal spindle distortion Minimal motor activation.

Stimulants ; (Methylphenidate, Amphetamines) ↑ ↑ \uparrow\uparrow ↑↑ SOL, ↑ ↑ \uparrow\uparrow ↑↑ WASO, ↓ \downarrow ↓ TST, ↓ \downarrow ↓ REM Increased wakefulness and alpha intrusion Increases sympathetic tone, heart rate, and blood pressure.

Opioids ; (Morphine, Methadone, Fentanyl) ↓ ↓ \downarrow\downarrow ↓↓ N3, ↓ \downarrow ↓ REM, ↑ \uparrow ↑ N1, Severe fragmentation Frequent arousals and alpha-delta sleep Induces Central Sleep Apneas (CSA) and Ataxic Breathing (Biot's).

Lipophilic Beta-Blockers ; (Propranolol, Metoprolol) ↑ \uparrow ↑ WASO, ↓ \downarrow ↓ TST, ↓ \downarrow ↓ REM, Insomnia Suppresses endogenous melatonin synthesis Nightmares, vivid dreams, sleep disruption.

Alcohol (Ethanol) Biphasic: Early ↑ \uparrow ↑ N3, ↓ \downarrow ↓ REM; Late ↑ \uparrow ↑ WASO, ↑ ↑ \uparrow\uparrow ↑↑ REM Rebound Autonomic arousal, alpha intrusion in late night Severe upper airway muscle relaxation, exacerbating OSA.